The Syneos Health Podcast

Episode 001: The Real-World Evidence Revolution

March 03, 2017 Jeffrey Stewart / David Thompson
Episode 001: The Real-World Evidence Revolution
The Syneos Health Podcast
More Info
The Syneos Health Podcast
Episode 001: The Real-World Evidence Revolution
Mar 03, 2017
Jeffrey Stewart / David Thompson
The passage of the 21st Century Cures Act earlier this year catapulted the concept of “real-world evidence” into the spotlight, with many biopharmaceutical companies wondering whether this could be the panacea the industry has been looking for to attain product success. We reflected on this topic with David Thompson, PhD, Senior Vice President, Real-World Evidence Consulting at inVentiv Health, after he moderated a keynote panel at the Biotech Showcase event alongside the popular JP Morgan Healthcare Conference in San Francisco this January. Bottom line, according to Thompson, is that it’s complicated – but the fact of the matter is that approval alone no longer gets you to the end zone; more likely, it will get you to the 50-yard line. Appropriate use of real-world evidence can provide some degree of advantage for products entering the marketplace. Listen in to learn more from this discussion on real-world evidence, including why it’s so complicated, where the FDA fits in, what it means to payers and how it can impact commercial success.

The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements, or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter.

The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. inVentiv Health reserves the right to make alterations or deletions to the content at any time without notice to you.

inVentiv Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content.

The information, data, and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any of inVentiv Health’s clients, customers or other contacts.

The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health.

Like what you’re hearing? Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Show Notes
The passage of the 21st Century Cures Act earlier this year catapulted the concept of “real-world evidence” into the spotlight, with many biopharmaceutical companies wondering whether this could be the panacea the industry has been looking for to attain product success. We reflected on this topic with David Thompson, PhD, Senior Vice President, Real-World Evidence Consulting at inVentiv Health, after he moderated a keynote panel at the Biotech Showcase event alongside the popular JP Morgan Healthcare Conference in San Francisco this January. Bottom line, according to Thompson, is that it’s complicated – but the fact of the matter is that approval alone no longer gets you to the end zone; more likely, it will get you to the 50-yard line. Appropriate use of real-world evidence can provide some degree of advantage for products entering the marketplace. Listen in to learn more from this discussion on real-world evidence, including why it’s so complicated, where the FDA fits in, what it means to payers and how it can impact commercial success.

The information, data, and other content contained in this podcast and any associated articles, sponsorships, advertisements, announcements, or other communications are provided for informational purposes only and should not be construed as professional advice of any kind, on any subject matter.

The content of the podcast contains general information and may not reflect current legal developments, verdicts or settlements. Moreover, the content is not guaranteed to be complete, correct, timely, current or otherwise up-to-date. inVentiv Health reserves the right to make alterations or deletions to the content at any time without notice to you.

inVentiv Health and its subsidiaries expressly disclaim all liability in respect to actions taken or not taken based on any or all of the podcast content.

The information, data, and other content contained in this podcast is not a reflection of, endorsed by or otherwise affiliated with, nor should it be attributed to, any of inVentiv Health’s clients, customers or other contacts.

The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.

If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health.

Like what you’re hearing? Be sure to rate and review us!

We want to hear from you! If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com.